Filing Analysis
Shoulder Innovations, Inc. announced the full commercial launch of its InSet™ I-135RFX Humeral Stem on April 27, 2026. The announcement was made via a press release furnished under Item 7.01 of Form 8-K.
Key Facts
- Full commercial launch of the InSet™ I-135RFX Humeral Stem announced on April 27, 2026.
- The disclosure was made under Item 7.01 (Regulation FD), meaning the information is furnished rather than filed.
- The company is an emerging growth company registered on the New York Stock Exchange (NYSE: SI).
Shoulder Innovations, Inc. entered into a 10-year lease agreement for a new 15,200 square foot corporate headquarters in Byron Center, Michigan. The agreement involves an estimated $4.4 million in rent payments over the initial term, with occupancy expected in late 2027.
Key Facts
- Agreement signed on April 13, 2026, with Ventura Office Park Lot #8, LLC.
- The facility will be approximately 15,200 square feet containing both office and warehouse space.
- The initial lease term is 10 years with two five-year extension options.
- Aggregate estimated rent payments are approximately $4.4 million over the initial term.
- The Company paid a $33,000 security deposit and a $0.5 million down payment for construction costs.
- Possession of the premises is expected in the fourth quarter of 2027.
Shoulder Innovations, Inc. announced its Q4 and full-year 2025 financial results and disclosed that Director Michael Carusi will not stand for re-election at the 2026 Annual Meeting of Stockholders.
Key Facts
- Financial results for the fourth quarter and year ended December 31, 2025, were released on March 10, 2026.
- Michael Carusi, a Class I director, notified the company on March 6, 2026, of his intent not to seek re-election.
- Mr. Carusi's term will conclude on the date of the 2026 Annual Meeting of Stockholders.
- The company explicitly stated there were no disagreements between Mr. Carusi and management or the Board.
Shoulder Innovations announced the immediate resignation of director Geoff Pardo and the concurrent appointment of Andrew Hykes to the Board of Directors. Mr. Hykes brings extensive medical device leadership experience, having previously served as CEO of Inari Medical and in various executive roles at Medtronic.
Key Facts
- Geoff Pardo resigned as a Class I director, member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee on February 26, 2026.
- Andrew Hykes was appointed as a Class I director and member of the Compensation Committee effective immediately to fill the vacancy.
- Andrew Hykes is currently the CEO of Okami Medical and was formerly the CEO of Inari Medical (Jan 2023 - May 2025).
- The company stated there were no disagreements between Mr. Pardo and the management or Board.